OptiBiotix Health plc (AIM: OPTI), a Life Sciences business developing products to tackle obesity, high cholesterol and diabetes is pleased to tell DirectorsTalk that it has raised £1,500,000, before expenses
OptiBiotix Health plc (AIM: OPTI), a Life Sciences business developing products to tackle obesity, high cholesterol and diabetes, has told DirectorsTalk about the appointment of Peter Wennström as a Non-Executive
Optibiotix Health Plc (LON:OPTI) this morning announced a new development agreement with Centro Sperimentale del Latte to synthesise and purify novel oligosaccharides from microbial strains. DirectorsTalk caught up with Stephen
Stephen O’Hara, CEO of OptiBiotix LON:OPTI, commented: “This development agreement reflects the progress we have made with our OptiBiotic technology platform. Increasing the number of microbial species is an exciting extension of our existing programme which
In an article published by The Scientist entitled ‘Microbes Play Role in Anti-Tumor Response’ it states that Gut microbiome composition can influence the effectiveness of cancer immunotherapy in mice. We
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, highcholesterol and diabetes, has told DirtectorsTalk about the filing of two new patents covering its cholesterol reducing product. This increases the number of patents from nine to eleven. The new patents reflect:- · The success
The following is part of a report produced by markets and markets entitled ‘Human Microbiome Market worth $658 Million by 2023’. DirectorsTalk caught up with Stephen O’Hara the CEO at
Optibiotix Health Plc (LON:OPTI) is one of the companies that will gain more awareness after the governments advisory group Public Health England saw it’s recent report leaked. The report highlights
OptiBiotix Health plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, has told DirectorsTalk about its results for the six months ended 31 May
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the successful completion of clinical studies on its capsular food supplement
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
